Intervention Review

You have free access to this content

Nebuliser systems for drug delivery in cystic fibrosis

  1. Tracey Daniels1,*,
  2. Nicola Mills2,
  3. Paul Whitaker3

Editorial Group: Cochrane Cystic Fibrosis and Genetic Disorders Group

Published Online: 30 APR 2013

Assessed as up-to-date: 26 MAR 2013

DOI: 10.1002/14651858.CD007639.pub2


How to Cite

Daniels T, Mills N, Whitaker P. Nebuliser systems for drug delivery in cystic fibrosis. Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD007639. DOI: 10.1002/14651858.CD007639.pub2.

Author Information

  1. 1

    York Teaching Hospital Foundation NHS Trust, York, UK

  2. 2

    Glenfield Hospital, Physiotherapy Department, Leicester, UK

  3. 3

    St James' Hospital, Regional Adult CF Unit, Ward 2, Gledhow Wing, Leeds, UK

*Tracey Daniels, York Teaching Hospital Foundation NHS Trust, Wiggington Road, York, YO31 8HE, UK. traceydaniels1@nhs.net.

Publication History

  1. Publication Status: New
  2. Published Online: 30 APR 2013

SEARCH

[Figure 1]
Figure 1. Study flow/ PRISMA diagram.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Tobramycin - conventional versus conventional, Outcome 1 Bronchoconstriction (nebuliser versus nebuliser).
[Analysis 1.2]
Analysis 1.2. Comparison 1 Tobramycin - conventional versus conventional, Outcome 2 Bronchoconstriction (compressor versus compressor).
[Analysis 1.3]
Analysis 1.3. Comparison 1 Tobramycin - conventional versus conventional, Outcome 3 Increased cough (nebuliser versus nebuliser).
[Analysis 1.4]
Analysis 1.4. Comparison 1 Tobramycin - conventional versus conventional, Outcome 4 Chest pain (nebuliser versus nebuliser).
[Analysis 1.5]
Analysis 1.5. Comparison 1 Tobramycin - conventional versus conventional, Outcome 5 FEV1 (% predicted).
[Analysis 1.6]
Analysis 1.6. Comparison 1 Tobramycin - conventional versus conventional, Outcome 6 Satisfaction with device.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Tobramycin - conventional versus VMT, Outcome 1 Treatment time (minutes).
[Analysis 2.2]
Analysis 2.2. Comparison 2 Tobramycin - conventional versus VMT, Outcome 2 Deposition (serum Cmax).
[Analysis 2.3]
Analysis 2.3. Comparison 2 Tobramycin - conventional versus VMT, Outcome 3 Deposition (serum AUC).
[Analysis 2.4]
Analysis 2.4. Comparison 2 Tobramycin - conventional versus VMT, Outcome 4 Deposition (sputum Cmax).
[Analysis 2.5]
Analysis 2.5. Comparison 2 Tobramycin - conventional versus VMT, Outcome 5 Deposition (sputum AUC).
[Analysis 2.6]
Analysis 2.6. Comparison 2 Tobramycin - conventional versus VMT, Outcome 6 Adherence.
[Analysis 2.7]
Analysis 2.7. Comparison 2 Tobramycin - conventional versus VMT, Outcome 7 Adverse events.
[Analysis 2.8]
Analysis 2.8. Comparison 2 Tobramycin - conventional versus VMT, Outcome 8 FEV1: reduction >10%.
[Analysis 2.9]
Analysis 2.9. Comparison 2 Tobramycin - conventional versus VMT, Outcome 9 FEV1: reduction >20%.
[Analysis 2.10]
Analysis 2.10. Comparison 2 Tobramycin - conventional versus VMT, Outcome 10 Device malfunctions.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Colistin - conventional versus AAD, Outcome 1 Treatment time.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Colistin - conventional versus AAD, Outcome 2 Deposition (lung uptake MBq).
[Analysis 3.3]
Analysis 3.3. Comparison 3 Colistin - conventional versus AAD, Outcome 3 Deposition (lung uptake as % of dose used).
[Analysis 3.4]
Analysis 3.4. Comparison 3 Colistin - conventional versus AAD, Outcome 4 FEV1 (% change).
[Analysis 3.5]
Analysis 3.5. Comparison 3 Colistin - conventional versus AAD, Outcome 5 Satisfaction with device.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Dornase alfa - conventional versus conventional, Outcome 1 Treatment time.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Dornase alfa - conventional versus conventional, Outcome 2 Adverse events: haemoptysis.
[Analysis 4.3]
Analysis 4.3. Comparison 4 Dornase alfa - conventional versus conventional, Outcome 3 Adverse events: chest pain.
[Analysis 4.4]
Analysis 4.4. Comparison 4 Dornase alfa - conventional versus conventional, Outcome 4 Adverse events:pharyngitis.
[Analysis 4.5]
Analysis 4.5. Comparison 4 Dornase alfa - conventional versus conventional, Outcome 5 Adverse events: voice alteration.
[Analysis 4.6]
Analysis 4.6. Comparison 4 Dornase alfa - conventional versus conventional, Outcome 6 Adverse events: cough.
[Analysis 4.7]
Analysis 4.7. Comparison 4 Dornase alfa - conventional versus conventional, Outcome 7 % Change in FEV1 (multiple nebuliser comparison).
[Analysis 4.8]
Analysis 4.8. Comparison 4 Dornase alfa - conventional versus conventional, Outcome 8 % Change in FEV1.
[Analysis 4.9]
Analysis 4.9. Comparison 4 Dornase alfa - conventional versus conventional, Outcome 9 FVC.
[Analysis 4.10]
Analysis 4.10. Comparison 4 Dornase alfa - conventional versus conventional, Outcome 10 FEF25-75.
[Analysis 5.1]
Analysis 5.1. Comparison 5 Dornase alfa - conventional versus AAD, Outcome 1 Deposition (sputum) (µg).
[Analysis 6.1]
Analysis 6.1. Comparison 6 Other aerosolised medication - conventional versus conventional, Outcome 1 Radio-labelled saline: deposition (mg).
[Analysis 6.2]
Analysis 6.2. Comparison 6 Other aerosolised medication - conventional versus conventional, Outcome 2 Carbenicillin: deposition (mg).
[Analysis 7.1]
Analysis 7.1. Comparison 7 Other aerosolised medication - conventional versus AAD, Outcome 1 Sodium chloride: deposition.
[Analysis 8.1]
Analysis 8.1. Comparison 8 Other aerosolised medication - conventional versus ultrasonic, Outcome 1 Amiloride: pulmonary deposition (µg).
[Analysis 8.2]
Analysis 8.2. Comparison 8 Other aerosolised medication - conventional versus ultrasonic, Outcome 2 Amiloride: extrapulmonary deposition (counts/s).
[Analysis 8.3]
Analysis 8.3. Comparison 8 Other aerosolised medication - conventional versus ultrasonic, Outcome 3 Amiloride: respiratory function tests.
[Analysis 8.4]
Analysis 8.4. Comparison 8 Other aerosolised medication - conventional versus ultrasonic, Outcome 4 SCG: treatment time (min).
[Analysis 8.5]
Analysis 8.5. Comparison 8 Other aerosolised medication - conventional versus ultrasonic, Outcome 5 SCG: deposition measured by urinary levels (mg).
[Analysis 8.6]
Analysis 8.6. Comparison 8 Other aerosolised medication - conventional versus ultrasonic, Outcome 6 SCG: residual medication in nebuliser (mg).